New drug combo targets tough cancers in early trial
NCT ID NCT06960395
First seen Mar 26, 2026 · Last updated May 05, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug called VIR-5525, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The goal is to find safe doses and see if the drug shrinks tumors. About 450 adults with cancers that cannot be removed by surgery or have spread will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health Research Institute
RECRUITINGScottsdale, Arizona, 85258-4566, United States
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
-
Princess Alexandra Hospital
RECRUITINGWoolloongabba, Queensland, 4102, Australia
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Conditions
Explore the condition pages connected to this study.